Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST
MNK: 97.84 (-0.29), BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)
3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 1.13 (+0.04), AGEN: 3.85 (unch), INO: 9.11 (-0.09), NBS: 3.27 (+0.02), OSIR: 14.87 (+0.13), TEVA: 57.09 (+0.33), ATHX: 1.30 (-0.03)
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
Today's Water-Logged And Getting Wetter Stock: Teva Pharmaceutical Industries (TEVA)
at The Street - Tue Dec 23, 11:18AM CST
Trade-Ideas LLC identified Teva Pharmaceutical Industries (TEVA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
TEVA: 57.09 (+0.33)
FDA clears expanded label for Granix
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 7:43AM CST
TEVA: 57.09 (+0.33)
FDA Approves Teva's GRANIX(R) (tbo-filgrastim) Injection for Self-Administration
Business Wire - Tue Dec 23, 7:00AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved GRANIX(R) (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use.
TEVA: 57.09 (+0.33)
Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST
MYL: 56.97 (+0.39), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Business Wire - Mon Dec 22, 7:00AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs Healthcare CEOs Unscripted Conference. Erez Vigodman, President & CEO will present on Tuesday, January 6, 2015 at 10:15 AM EST.
TEVA: 57.09 (+0.33)
Teva Pharmaceutical Industries Rises 2.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:47PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $56.54 to a high of $58.61. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $56.77 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.09 (+0.33)
After Yesterday's Rally of 2.38% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:47PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $56.54 to a high of $58.61. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $56.77 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.09 (+0.33)
FDA clears pediatric formulation of Teva hay fever med
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:26AM CST
TEVA: 57.09 (+0.33)
Teva Announces FDA Approval of QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis
Business Wire - Fri Dec 19, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved QNASL(R) (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age.
TEVA: 57.09 (+0.33)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.13 (+0.05), TEVA: 57.09 (+0.33), ITCI: 17.99 (+0.16), BCLI: 3.85 (+0.22), OMER: 22.09 (+0.48), NVS: 93.91 (+0.66)
DirecTV Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Thu Dec 18, 11:52AM CST
HCA: 74.89 (-0.11), HD: 103.56 (-0.20), LB: 85.06 (unch), GS: 195.89 (+0.39), CPT: 75.44 (-0.56), UNH: 102.68 (-0.17), DTV: 86.82 (-0.05), AMGN: 160.67 (+3.15), TEVA: 57.09 (+0.33), SRE: 112.09 (+1.76), CIT: 48.20 (-0.12), BRK.B: 151.54 (-0.21), BRK.A: 226,515.00 (-1,115.00)
Micro Market Monitor: North American Intrauterine Contraceptive Devices Market - Forecasts to 2019
M2 - Thu Dec 18, 6:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/mmqf4w/micro_market) has announced the addition of the "Micro Market Monitor: North American Intrauterine Contraceptive Devices Market" report to their offering. The North American Intrauterine Contraceptive Devices (IUCD) market is estimated to grow at a CAGR of 0.3% from 2014 to 2019. The growth of this market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception, fewer side effects of IUCDs, implementation of the Affordable Care Act (ACA), rising initiatives of private firms directed at reducing abortion-related expenses, funds/grants for IUCD products, and technological advancements. Moreover, the rising number of players in this segment and technological advancements are creating growth opportunities for the North American intrauterine contraceptive devices market. However, high cost of treatment, threat of causing pelvic inflammatory infection (PID), threat of causing ectopic pregnancy, high rate of complications in unplanned pregnancies, and the need for compulsory assistance of a medical professional for the insertion of IUCDs is restraining the growth of the IUCD market in North America. In this report, the North American intrauterine contraceptive devices market has been broadly classified on the basis of types, which include hormonal IUCDs and copper IUCDs. The hormonal IUCD market segment accounts for the largest market share of 83.4% of the North American IUCD market. Factors such as safety, easy removal, lighter periods, and the increasing adoption of hormonal IUD products such as Mirean and Skyla in the U.S. are driving the growth of this market. Key Topics Covered: 1. Introduction 2 Market Overview 3 Market Dynamics 4 Intrauterine Contraceptive Devices (Iucd) Market, By Type 5 Competitive Landscape Companies Mentioned: - Bayer Healthcare - Teva Pharmaceutical Industries - Actavis - Medicines360 - Trimedic Supply Network - Medisafe Distribution - Pace Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/mm...cro_market
TEVA: 57.09 (+0.33)
Postherpetic Neuralgia - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/489mg3/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Allergan - Acorda Therapeutics - Daewoong Pharmaceutical - Pfizer - Purdue Pharma - Teva Pharmaceutical Industries - Nuvo Research Inc. - Arcion Therapeutics, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - Bial - Portela & Ca, S.A. - Spinifex Pharmaceuticals Pty Limited - Relmada Therapeutics, Inc. - Aestus Therapeutics, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Immune Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/48...stherpetic
AGN: 210.12 (+0.95), TEVA: 57.09 (+0.33), IMNP: 1.89 (+0.02), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Fitch Affirms Teva's Ratings at 'BBB+'; Outlook Stable
Business Wire - Wed Dec 17, 3:36PM CST
Fitch Ratings has affirmed the ratings of Teva Pharmaceutical Industries Limited (Teva) and its subsidiaries at 'BBB+'. The Rating Outlook is Stable.
TEVA: 57.09 (+0.33)
Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan
PR Newswire - Wed Dec 17, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, December 16, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,068.87, down 0.65% and the NASDAQ Composite closed at 4,547.83, down 1.24%. The S&P 500 finished the session 0.85% lower at 1,972.74. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, whereas the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
AGN: 210.12 (+0.95), ENDP: 72.10 (+0.34), TEVA: 57.09 (+0.33), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11)
Pfizer, Inc. Invests in Growth... Literally
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 17, 7:06AM CST
Source: Pfizer Pfizer Inc . locked up commercial rights to Opko Health 's long-lasting human growth hormone in a deal worth hundreds of millions of dollars. The agreement helps insulate Pfizer's existing HGH drug from potential competition and...
GILD: 91.29 (+1.84), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33)